Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals insider Jolanda Howe has filed to sell 968 shares of common stock. The planned sale through Morgan Stanley Smith Barney on NASDAQ has an aggregate market value of $100,478.40, with 51,393,574 common shares shown as outstanding.
The 968 shares to be sold were acquired on January 31, 2026 as restricted stock units vesting under a registered plan, received as compensation for services to the company. In the prior three months, Howe sold 926 shares on January 22, 2026 for $86,419.16 and 842 shares on January 26, 2026 for $80,993.67.
Mirum Pharmaceuticals insider Peter Radovich has filed a Form 144 indicating an intent to sell 2,631 shares of common stock through Morgan Stanley Smith Barney LLC on or about February 2, 2026 on NASDAQ, with an aggregate market value of $273,097.80.
The 2,631 shares were acquired on January 31, 2026 as restricted stock units vesting under a registered plan, as compensation for services to the issuer. In the prior three months, Radovich sold 2,382 shares for $222,300.69 on January 22, 2026 and 3,143 shares for $302,331.46 on January 26, 2026.
Mirum Pharmaceuticals shareholder Christopher Peetz has filed a Rule 144 notice to sell 9,108 shares of common stock. The planned sale, through Morgan Stanley Smith Barney on the NASDAQ around 02/02/2026, has an aggregate market value of $945,410.40, with 51,393,574 shares outstanding.
The shares to be sold were acquired on 01/31/2026 when restricted stock units vested under a registered plan as compensation for services to Mirum. The filing also notes earlier January 2026 sales of 7,098 and 6,831 shares of common stock for gross proceeds of $662,422.46 and $657,087.57, respectively.
Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported new equity awards in the company. On January 28, 2026, she received stock options for 7,680 shares of common stock with an exercise price of $100.85 per share, vesting over four years starting one year after that date.
She was also granted 4,970 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 9,000 performance restricted stock units previously granted on January 23, 2024 were confirmed to have met their performance criteria, and will vest two-thirds on March 15, 2026 and one-third on March 15, 2027.
Mirum Pharmaceuticals reported new equity awards for its Chief Medical Officer, Joanne Quan, dated January 28, 2026. She received a stock option for 18,140 shares at an exercise price of $100.85 per share. One quarter of this option vests one year after January 28, 2026, with the remaining shares vesting in 36 equal monthly installments.
Quan was also granted 11,760 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 20,000 performance restricted stock units (PSUs) granted on January 23, 2024, had their performance criteria determined to be met on January 28, 2026. Two thirds of the PSU shares will vest on March 15, 2026 and the remaining one third on March 15, 2027.
Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt received new equity awards on January 28, 2026. He was granted stock options for 18,140 shares of common stock at an exercise price of $100.85 per share, plus 11,760 restricted stock units and 20,000 performance-based restricted stock units.
The stock options vest over four years, with one-quarter vesting one year after January 28, 2026 and the remainder in 36 equal monthly installments. The restricted stock units vest in three equal annual installments from the same date. The performance units vest two-thirds on March 15, 2026 and one-third on March 15, 2027 after performance criteria were met.
Mirum Pharmaceuticals’ President and COO Peter Radovich reported new equity awards dated January 28, 2026. He received a stock option for 25,120 shares of common stock at an exercise price of $100.85 per share.
He was also granted 16,280 restricted stock units, each representing one share of common stock, vesting in three equal annual installments starting January 28, 2027. In addition, 34,500 performance restricted stock units tied to performance criteria that were determined met on January 28, 2026 will vest as follows: two-thirds on March 15, 2026 and the remaining one-third on March 15, 2027. All awards are reported as directly owned.
Mirum Pharmaceuticals, Inc. CEO and director Christopher Peetz reported new equity awards, including stock options and stock units granted on January 28, 2026. He received stock options for 67,000 shares at an exercise price of $100.85, vesting over four years starting one year after the vesting commencement date.
Peetz was also granted 43,500 restricted stock units, vesting in three equal annual installments on each anniversary of January 28, 2026. In addition, 75,000 previously granted performance restricted stock units had their performance criteria confirmed as met; two-thirds of these shares vest on March 15, 2026 and one-third on March 15, 2027. All reported derivative holdings are listed as directly owned.
Mirum Pharmaceuticals, Inc. insider Jolanda Howe filed a notice to sell restricted shares under Rule 144. The filing covers the proposed sale of 842 shares of common stock, with an aggregate market value of 81606.64, through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on NASDAQ.
The 842 shares were acquired on 01/23/2026 as restricted stock units vesting under a registered compensation plan for services to the issuer. The filing notes that 926 shares of common stock were sold on 01/22/2026 for gross proceeds of 86419.16, and that 51393574 shares of common stock were outstanding.
Mirum Pharmaceuticals, Inc. insider plans a modest stock sale under Rule 144. A holder has filed to sell 1,053 shares of Mirum common stock on NASDAQ through Morgan Stanley Smith Barney LLC, with an approximate sale date of 01/26/2026 and an aggregate market value of 102,056.76.
The 1,053 shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services rendered to Mirum. Over the past three months, the same seller disposed of 1,421 shares of common stock on 01/22/2026 for gross proceeds of 132,615.15. Shares outstanding were 51,393,574 at the time referenced.